New Drug Boosts Breast Cancer Survival

In an article in The Lancet, German researchers report that certain breast cancer patients who switch to the aromatase inhibitor drug anastrozole (Arimidex) after two to three years of treatment with tamoxifen live longer and are more likely to remain cancer-free. More from the Washington Post.